{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.039","pValueComment":"P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG001","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.458","pValueComment":"P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG002","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.008","pValueComment":"P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG003","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.029","pValueComment":"P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.45","value":"-11.6"},{"groupId":"OG001","spread":"16.81","value":"-6.4"},{"groupId":"OG002","spread":"17.28","value":"-11.5"},{"groupId":"OG003","spread":"22.42","value":"-13.9"},{"groupId":"OG004","spread":"19.49","value":"-6.0"}]}],"title":"Week 12 (n=44, 51, 50, 49, 83)"},{"categories":[{"measurements":[{"comment":"Participants were not dosed with 1 mg LY3009104 after Week 12, therefore mean and SD were not calculated.","groupId":"OG000","spread":"NA","value":"NA"},{"groupId":"OG001","spread":"13.89","value":"-6.9"},{"groupId":"OG002","spread":"19.00","value":"-9.2"},{"groupId":"OG003","spread":"21.62","value":"-13.7"},{"comment":"Participants were not dosed with placebo after Week 12, therefore mean and SD were not calculated.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Week 24 (n=0, 50, 48, 45, 0)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"49"},{"groupId":"OG004","value":"83"}],"units":"Participants"}],"description":"ESR is a laboratory analyte that is an indicator of inflammation. Decreases represent reductions in inflammation.","dispersionType":"Standard Deviation","groups":[{"description":"1 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG000","title":"1 mg LY3009104"},{"description":"2 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.\n\nMTX was administered orally as background therapy.","id":"OG001","title":"2 mg LY3009104"},{"description":"4 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.\n\nMTX was administered orally as background therapy.","id":"OG002","title":"4 mg LY3009104"},{"description":"8 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.\n\nMTX was administered orally as background therapy.","id":"OG003","title":"8 mg LY3009104"},{"description":"Placebo administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG004","title":"Placebo"}],"paramType":"MEAN","populationDescription":"All randomized participants who received study drug in Parts A and B and had ESR evaluated at analysis time points.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 12 and 24","title":"Mean Change From Baseline to Weeks 12 and 24 in Erythrocyte Sedimentation Rate (ESR)","type":"SECONDARY","unitOfMeasure":"mm/hr"}